Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Evidence for Evolution02:55

The Evidence for Evolution

47.7K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
47.7K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

572
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
572
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

717
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
717
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

332
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
332
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

508
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
508
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

366
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
366

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current Strategies for Optimizing Antithrombotic Therapy in Patients with Chronic Coronary Syndrome: A Dynamic Approach.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Persisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry.

Journal of clinical medicine·2026
Same author

Insights Into the Natural History of Recurrent Myocarditis, A Multicenter International Study (Re-Myo Study).

Journal of the American Heart Association·2026
Same author

Adverse cardiovascular events in coronary Plaques not undeRgoing pErcutaneous coronary intervention evaluateD with optIcal Coherence Tomography. The PREDICT-AI risk model.

Open heart·2025
Same author

Predictors and Impact of Cardiogenic Shock in Oldest-Old ST-Elevation Myocardial Infarction Patients.

Journal of clinical medicine·2025
Same author

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis.

ESC heart failure·2024

Related Experiment Video

Updated: Jan 20, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K

Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach.

Enrico Fabris1, Marco Merlo1, Claudio Rapezzi2

  • 1Cardiovascular Department, Azienda Sanitaria Universitaria Integrata (ASUITS), University of Trieste, Trieste, Italy.

Drugs
|August 22, 2019
PubMed
Summary

Sacubitril/valsartan, a new heart failure (HF) medication, significantly reduces cardiovascular death and hospitalizations. This angiotensin receptor-neprilysin inhibitor (ARNI) represents a major advancement in HF treatment.

More Related Videos

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

16.7K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

Related Experiment Videos

Last Updated: Jan 20, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K
Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
12:12

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice

Published on: February 14, 2017

16.7K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Heart failure (HF) presents a significant socio-economic burden, necessitating novel therapeutic strategies.
  • Current HF treatment often focuses on inhibiting the renin-angiotensin-aldosterone and sympathetic nervous systems.
  • A paradigm shift is emerging towards enhancing endogenous natriuretic peptides.

Purpose of the Study:

  • To review the evidence supporting sacubitril/valsartan as a novel therapeutic strategy for heart failure.
  • To highlight the role of angiotensin receptor-neprilysin inhibitors (ARNI) in HF management.
  • To assess the impact of sacubitril/valsartan on patient outcomes and quality of life.

Main Methods:

  • Review of clinical trial data and scientific literature on sacubitril/valsartan.
  • Comparison of sacubitril/valsartan efficacy against traditional HF therapies like enalapril.
  • Analysis of composite endpoints including cardiovascular death, HF hospitalization, and disease progression.

Main Results:

  • Sacubitril/valsartan demonstrated a reduction in the composite endpoint of cardiovascular death or HF hospitalization compared to enalapril.
  • The drug improved quality of life in patients with heart failure on evidence-based therapy.
  • Evidence supports sacubitril/valsartan as a disease-modifying therapy for HF.

Conclusions:

  • Sacubitril/valsartan, a first-in-class ARNI, represents a significant advancement in pharmacological therapy for heart failure.
  • This agent offers a new treatment strategy by enhancing natriuretic peptides.
  • The findings support sacubitril/valsartan as a disease-modifying therapy, marking a substantial step forward in HF treatment research.